{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T18:29:13Z","timestamp":1655058553793},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ghpjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.genhosppsych.2014.01.007","type":"journal-article","created":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T15:01:27Z","timestamp":1390575687000},"page":"361.e1-361.e2","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Varenicline-induced acute dystonic reaction: a case report"],"prefix":"10.1016","volume":"36","author":[{"given":"Ali Ulvi","family":"Uca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan H\u00fcseyin","family":"Kozak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faruk","family":"Uguz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0005","first-page":"81","article-title":"Sigara birakma ba\u015farisini etkileyen fakt\u00f6rler","volume":"14","author":"Arg\u00fcder","year":"2013","journal-title":"Turk Toraks Derg"},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/ajp.153.10.1","article-title":"Practice guideline for the treatment of patients with nicotine dependence","volume":"153","author":"American Psychiatric Association","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"Varenicline Phase 3 Study Group. Efficacy of varenicline, an \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial","volume":"296","author":"Jorenby","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0080","doi-asserted-by":"crossref","first-page":"664","DOI":"10.5993\/AJHB.32.6.10","article-title":"Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis","volume":"32","author":"Nides","year":"2008","journal-title":"Am J Health Behav"},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0020","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00002018-200932060-00006","article-title":"Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study","volume":"32","author":"Kasliwal","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0025","author":"US Food and Drug Administration"},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/JCP.0b013e31827c0117","article-title":"Neuropsychiatric adverse events of varenicline: a systematic review of published reports","volume":"33","author":"Ahmed","year":"2013","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0035","first-page":"344","article-title":"Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis","volume":"4","author":"Prochaska","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0897190013504961","article-title":"Safety of varenicline in patients with cardiovascular disease","volume":"27","author":"Haber","year":"2014","journal-title":"J Pharm Pract."},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0045","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2165\/00002018-199716030-00004","article-title":"Drug-induced movement disorders","volume":"16","author":"Jim\u00e9nez-Jim\u00e9nez","year":"1997","journal-title":"Drug Saf"},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0050","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.nbd.2011.01.026","article-title":"The functional neuroanatomy of dystonia","volume":"42","author":"Neychev","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0055","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrneurol.2009.160","article-title":"Primary dystonia: molecules and mechanisms","volume":"5","author":"Tanabe","year":"2009","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0060","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1368-5031.2006.00955.x","article-title":"The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline","volume":"60","author":"Foulds","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0065","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.schres.2013.02.015","article-title":"Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study","volume":"146","author":"Fatemi","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006103.pub6","article-title":"Nicotine receptor partial agonists for smoking cessation","volume":"4","author":"Cahill","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.genhosppsych.2014.01.007_bb0075","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1017\/S1461145711001647","article-title":"Human electrophysiological correlates of learned irrelevance: effects of the muscarinic M1 antagonist biperiden","volume":"15","author":"Klinkenberg","year":"2012","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834314000115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834314000115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T03:32:22Z","timestamp":1538883142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834314000115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0163834314000115"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2014.01.007","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Varenicline-induced acute dystonic reaction: a case report","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2014.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}